case 2: testing for egfr in lung adenocarcinoma
Published 5 years ago • 141 plays • Length 5:00Download video MP4
Download video MP3
Similar videos
-
6:59
case 2: diagnosing pd-l1 and egfr lung adenocarcinoma
-
5:13
case 2: frontline therapy in egfr-mutated lung cancer
-
3:09
case 2: osimertinib in egfr-mutated lung cancer
-
5:34
case 2: pd-l1 and egfr lung adenocarcinoma
-
1:01:27
molecular testing for egfr mutations: what pathologists need to know
-
58:24
time for even more precision in testing and treatment of egfr-mutated nsclc
-
4:28
mutation testing for advanced lung cancer
-
30:32
2023 best of lung: targeted therapies in lung cancer
-
5:55
a case of egfr-mutant non–small cell lung cancer
-
59:19
precision oncology in early-stage lung cancer, with adjuvant egfr-targeted therapy leading the way
-
3:47
case overview: egfr-positive nsclc
-
1:41
egfr mutations in patients with lung cancer
-
2:19
patient summary: egfr-mutant stage 4 lung adenocarcinoma
-
1:06
dr. goldman on targeted therapy options for egfr-, alk-, and ros1-mutated nsclc
-
2:26
egfr mutations in nsclc
-
0:48
current role of immunotherapy in egfr-mutant lung cancer
-
5:50
targeted therapy in egfr exon 20-mutant non–small cell lung cancer
-
3:36
testing and recommendations: egfr-mutated stage iv nsclc
-
1:04
molecular testing in egfr mutant driven nsclc